Therapy

Pan-Coronavirus Therapy — targeting the viral genome with Cas13

Pan-Coronavirus Therapy

Pan-Coronavirus Therapy using a Cas13-guideRNA system. The antiviral effect is based on up to 5 Cas13-guideRNAs, which target and disrupt the Coronavirus RNA genome in all currently known variations, resulting in a complete blocking of viral replication in lung cells after 24h.

read more

Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy)

Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy)

Cardiovascular disease is the number one cause of death worldwide. Scientists at the University Medical Center Göttingen developed a gene therapy (TBX5 re-expression) for use in the prevention and acute treatment of a heart disease and associated complications (e.g. cardiac arrhythmia and sudden cardiac death).

read more

Pharmacologically controlled vector for CNS gene therapies

Pharmacologically controlled vector for CNS gene therapies

Gene therapies are irreversible and not controlable in case of side effects. We offer a pharmacologically controlled one-vector expression system of a therapeutic factor (i.e. GDNF) with zero background expression, based on mifepristone (Mfp)-Gene Switch system, for the therapy of neurological diseases.

read more

Targeted Demethylating Gene Therapy of Fibrosis

Targeted Demethylating Gene Therapy of Fibrosis

All-in-one construct dCas9-TET3CD-(target gene)-sgRNA for targeted fibrosis therapy through demethylation of the genes RASAL1, LRFN2, KLOTHO (i.e. in heart, kidney, liver, lung, cancer). Normal re-expression of these genes has been achieved successfully in vitro and in vivo as well as a reduction of fibrosis.

read more

Prevention of Fibrosis and Organ Protection

Prevention and treatment of of Fibrosis and Chronic Injury progression

Prevention of Fibrosis and Organ Protection by preconditioning cells via ARNT regulation, i.e. via low-dose tacrolimus, GPI-1046, LB100 or via gene-therapy.

read more

1-vector otoferlin DFNB9 gene therapy

1-vector otoferlin DFNB9 gene therapy

Due to the large OTOF size a one-vector delivery has remained challenging.Our technology: Gene-therapy of the otoferlin gene (OTOF) with overloaded AAV virus mediated delivery into the cochlea. In vivo proof-of-concept successfully achieved.

read more

Leucodistrophy-Repositioning: Laquinimod for Zellweger-Syndrome

Leucodistrophy-Repositioning: Laquinimod for Zellweger-Syndrome

Zellweger Syndrome spectrum, an orphan disease, is a peroxisomal biogenesis disorder with no treatment currently available. We offer the use of the clinically known Laquinimod (developed for multiple sclerosis) for the therapy of Zellweger Syndrom, for which we achieved successfully an in vivo proof-of-concept.

read more

Bio-engineered neuronal organoids from human stem cells

Bio-engineered neuronal organoids from human stem cells

Scientists at the University Medical Center Göttingen, Germany developed a reproducible, robust and fully defined method for serum-free production of human bio-engineered neuronal organoids (BENOs) from stem cells. This new method will allow for reproducible production of oganoids with fully functional neuronal network activity.

read more

New bifunctional Prodrugs with cleavable linker for targeted tumor therapy (ADC)

New bifunctional Prodrugs with cleavable linker for targeted tumor therapy (ADC)

Scientists at the University of Göttingen in Germany developed new and highly potent drugs with cleavable chemical linkers to develop tumor specific antibodies for selective tumor therapy (ADC). The soluble prodrugs are activated into highly cytotoxic drugs only in targeted tumor cells.

read more

Improved marker vaccine against classical swine fever

Improved marker vaccine against classical swine fever

Scientists at the University of Veterinary Medicine Hanover developed a new marker vaccine for classical swine fever based on chimeric pestiviruses with improved DIVA (Differentiating Infected from Vaccinated Animals) properties. The used marker Erns is a chimeric sequence of two different and remotely related pestiviruses.

read more

Prodrugs/drugs for a selective ADEPT/ADC tumor therapy

Prodrugs/drugs for a selective ADEPT/ADC tumor therapy

Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.

read more

Humanized anti-CCR2 Antibody for the Therapy of MS and RA

Humanized anti-CCR2 Antibody for the Therapy of MS and RA

Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA).The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.

read more

New therapy for amyotrophic lateral sclerosis

New therapy for amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is one of the most common degenerative neuromuscular diseases worldwide and characterized by rapidly progressive weakness and muscle atrophy throughout the body. Scientists at the University of Göttingen developed a new neuroprotective therapeutic approach for ALS.

read more

Search

A subsidiary of

Georg-August-Universität Göttingen